🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,027 results for “ERA” Clear

  1. Lucinactant for Inhalation

    WINDTREE THERAPEUTICS INC /DE/

    Respiratory Distress Syndrome, Newborn

    phase 2 other terminated

    1 trial

  2. Lucinactant for inhalation

    WINDTREE THERAPEUTICS INC /DE/

    Respiratory Distress Syndrome

    phase 2 other terminated

    2 trials

  3. Lutathera 370 MBq/mL solution for infusion, ATEZOLIZUMAB, Tevimbra 100 mg concentrate for solution for infusion, CARBOPLATIN, LysaKare 25 g/25 g solution for infusion, NETSPOT, ETOPOSIDE

    Novartis Pharmaceuticals

    Extensive stage small cell lung cancer (ES-SCLC)

    phase 2 small molecule active

    1 trial

  4. Lutathera 370 MBq/mL solution for infusion, LysaKare 25 g/25 g solution for infusion

    The George Institute

    Neuroendocrine tumor

    phase 2 small molecule active

    1 trial

  5. Lynparza 100 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., Faslodex 250 mg solution for injection., Lynparza 150 mg film-coated tablets, Zoladex 3.6 mg Implant

    Ningbo Cancer Hospital

    ER-positive and HER2-negative metastatic or locally advanced breast cancer with either a germline or somatic BRCA mutation, or a deleterious alteration of other genes involved in homologous recombination repair (HRR) or in MSI status.

    phase 2 small molecule active

    1 trial

  6. Lynparza 150 mg film-coated tablets, Lynparza 100 mg film-coated tablets

    Verona Pharma Ireland Limited

    Patients with metastatic PDAC, who have not progressed following completion of at least 16 weeks (can be more) of any multiagent first-line chemotherapy

    phase 2 small molecule active

    1 trial

  7. LysaKare 25 g/25 g solution for infusion, Lutathera 370 MBq/mL solution for infusion

    Advanced Accelerator Applications

    somatostatin receptor positive gastroenteropancreatic neuroendocrine (GEP-NET) tumors, pheochromocytoma and paragangliomas

    phase 2 small molecule active

    1 trial

  8. M1774, M1774, M1774, M1774, M4076, Zejula 100 mg film-coated tablets

    Merck Sharp and Dohme

    Epithelial ovarian cancer that progressed on prior PARP inhibitor therapy

    phase 2 small molecule active

    1 trial

  9. MAU868

    Vera Therapeutics

    BK Virus Infection

    phase 2 small molecule completed

    1 trial

  10. MAb-3F8

    United Therapeutics Europe Ltd

    Primary Refractory Neuroblastoma

    phase 2 mab terminated

    1 trial

  11. MBG453, VENETOCLAX, VENETOCLAX, AZACITIDINE, VENETOCLAX

    Novartis Pharmaceuticals

    intermediate, high or very high risk MDS in adult patients chronic Myelomonocytic Leukemia - 2 (CMML-2) Acute Myeloid Leukemia (AML) in adult patients unfit for chemotherapy

    phase 2 small molecule active

    1 trial

  12. MCLA-128

    Partner Therapeutics Limited

    Solid Tumors

    phase 2 small molecule active

    1 trial

  13. MDGN201 TARGTEPO

    Avalo Therapeutics

    Anemia of End Stage Renal Disease

    phase 2 mab terminated

    1 trial

  14. MDNA11

    Medicenna Therapeutics

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  15. MDNA55

    Medicenna Therapeutics

    Glioblastoma

    phase 2 small molecule completed

    1 trial

  16. METFORMIN , The placebo components are propylene glycol, neoPCLO/W, fenonip XB and purified water., METHYL AMINOLEVULINATE

    The George Institute

    Actinic keratoses

    phase 2 small molecule active

    1 trial

  17. MK0594

    VYNE Therapeutics

    Urinary Incontinence

    phase 2 small molecule completed

    1 trial

  18. ML-004 (IR)/(ER) tablet

    MapLight Therapeutics

    Autism Spectrum Disorder

    phase 2 small molecule active

    2 trials

  19. ML-007C-MA

    MapLight Therapeutics

    Psychosis Associated With Alzheimer's Disease

    phase 2 small molecule active

    2 trials

  20. ML-007C-MA

    MapLight Therapeutics

    Schizophrenia

    phase 2 small molecule active

    1 trial

  21. MLS-101 (Part I)

    Mineralys Therapeutics

    Hypertension, Renal

    phase 2 small molecule completed

    1 trial

  22. MOR 106

    Lakefront Biotherapeutics NV

    Atopic Dermatitis

    phase 2 small molecule terminated

    1 trial

  23. MOR106

    Lakefront Biotherapeutics NV

    Atopic Dermatitis

    phase 2 small molecule terminated

    1 trial

  24. MRX-6

    Akari Therapeutics Plc

    Atopic Dermatitis

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources